

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	William Lay
Date of last notice	17 January 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Noble House Consulting Ltd - a director-related entity.
Date of change	27 January 2023
No. of securities held prior to change	12,500,000 Fully Paid Ordinary Shares 1,666,667 CPHO Options (\$0.25, 2/11/2024) 10,000,000 CPHOPT41 Options (\$0.18, 6/09/2024) 10,000,000 CPHOPT42 Options (\$0.25, 6/09/2024) 10,000,000 CPHPERR43 Performance Rights
Class	CPHOD Options (\$0.08, 31/01/2027)
Number acquired	2,500,000
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	2,500,000 CPHOD Options issued as free attaching options for Mr Lay's participation into the placement announced on 1 August 2022. Please refer to Resolution 13 of the Notice of Meeting dated 24 November 2022 for further information.
No. of securities held after change	12,500,000 Fully Paid Ordinary Shares 1,666,667 CPHO Options (\$0.25, 2/11/2024) 2,500,000 CPHOD Options (\$0.08, 31/01/2027) 10,000,000 CPHOPT41 Options (\$0.18, 6/09/2024) 10,000,000 CPHOPT42 Options (\$0.25, 6/09/2024) 10,000,000 CPHOPT43 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	2,500,000 CPHOD Options (\$0.08, 31/01/2027) issued as free attaching options for Mr Lay's participation into the placement announced on 1 August 2022. Please refer to Resolution 13 of the Notice of Meeting dated 24 November 2022 for further information.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Linton
Date of last notice	17 January 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Canaccord Genuity Corp <Bruce Linton A/C> is a nominee entity for director, Bruce Linton.
Date of change	27 January 2023
No. of securities held prior to change	<u>Direct:</u> 5,411,884 Fully Paid Ordinary Shares 30,000,000 CPHOPT33 Options(\$0.039, 23/12/2025) <u>Indirect:</u> Canaccord Genuity Corp <Bruce Linton A/C> 5,000,000 Fully Paid Ordinary Shares
Class	CPHOPT46 Options (\$0.09, 17/01/2024) CPHOD Options (\$0.08, 31/01/2027)
Number acquired	10,000,000 CPHOPT46 Options (\$0.09, 17/01/2024) 5,000,000 CPHOD Options (\$0.08, 31/01/2027)
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<p>10,000,000 CPHOPT46 Options (\$0.09, 17/01/2024) issued for nil cash consideration as a component of Mr Bruce Linton's remuneration package as a Non-Executive Director of the Company.</p> <p>Please refer to Resolution 1 of the Notice of Meeting dated 24 November 2022 for further information.</p> <p>5,000,000 CPHOD Options issued as free attaching options for Mr Linton's participation into the placement announced on 1 August 2022.</p> <p>Please refer to Resolution 14 of the Notice of Meeting dated 24 November 2022 for further information.</p>
No. of securities held after change	<p><u>Direct:</u></p> <p>5,411,884 Fully Paid Ordinary Shares 30,000,000 CPHOPT33 Options (\$0.039, 23/12/2025)</p> <p><u>Indirect:</u></p> <p><i>Canaccord Genuity Corp <Bruce Linton A/C></i></p> <p>5,000,000 Fully Paid Ordinary Shares 10,000,000 CPHOPT46 Options (\$0.09, 17/01/2024) 5,000,000 CPHOD Options (\$0.08, 31/01/2027)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>CPHOPT46 Options (\$0.09, 17/01/2024) issued as a component of Mr Bruce Linton's remuneration package as a Non-Executive Director of the Company.</p> <p>Please refer to Resolution 1 of the Notice of Meeting dated 24 November 2022 for further information.</p> <p>5,000,000 CPHOD Options (\$0.08, 31/01/2027) issued as free attaching options for Mr Linton's participation into the placement announced on 1 August 2022.</p> <p>Please refer to Resolution 14 of the Notice of Meeting dated 24 November 2022 for further information.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.